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Abstract
Introduction Cushing’s disease is a rare disorder char-
acterized by overproduction of ACTH from a pituitary
adenoma leading to hypercortisolemia that in turn leads to
increased morbidity and mortality.
Methods Here we review the comorbidities associated
with Cushing’s disease and their impact on quality of life
and mortality.
Results Recent evidence suggests that correction of hy-
percortisolemia may not lead to complete resolution of co-
morbidities associated with this condition. In particular,
increased cardiovascular risk may persist despite long-term
remission of hypercortisolemia. This may be related to per-
sistence of visceral adiposity, adverse adipokine profile,
glucose intolerance, hypertension, dyslipidemia, atheroscle-
rosis and a procoagulant phenotype. Prior prolonged exposure
to glucocorticoids also may have irreversible effects on the
central nervous system, leading to persistent cognitive and
mood alterations. Osteoporosis and fractures, especially ver-
tebral fractures, can further add to morbidity and a poor
quality of life. Normalization of cortisol levels leads to sig-
nificant improvement in comorbidities but long-term data
regarding complete resolution are lacking and need further
study.
Conclusion Early diagnosis and treatment of hypercorti-
solemia, aggressive management of comorbidities along
with long-term follow-up is crucial for the optimal recov-
ery of these patients.
Keywords Cushing’s disease  Hypercortisolemia 
Mortality  Morbidity
Introduction
Cushing’s disease (CD) is a rare disorder caused by over-
production of adrenocorticotrophin hormone (ACTH) by a
pituitary adenoma that stimulates excess cortisol secretion
from the adrenal glands [1]. Its incidence is 1.2–2.4 per
million and prevalence is *40 per million population [2,
3]. CD accounts for 75–80 % of cases with ACTH-de-
pendent Cushing’s syndrome (CS).
The clinical presentation of CD can be highly variable
and the diagnosis can often be challenging in cases with
mild or cyclic hypercortisolism, especially given the
overlap in symptoms in individuals with and without the
disorder [1]. This may delay the diagnosis for 2–4 years
[3–5]. Hypercortisolemia is associated with increased
morbidity and mortality. Resection of the adenoma via
transsphenoidal surgery (TSS) remains the optimal treat-
ment. Medical therapy (steroidogenesis inhibitors, agents
that decrease ACTH levels and glucocorticoid receptor
antagonists) with or without pituitary radiotherapy may be
needed [1] to normalize cortisol and/or its action. In ad-
dition, management of comorbidities (Table 1) is impor-
tant because of increased cardiovascular risk despite
remission [3–8]. We here review the comorbidities asso-
ciated with CD and their impact on quality of life and
mortality.
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Mortality in CD
Multiple studies show that the standardized mortality ratio
(SMR) is increased in CD (1.7–4.8) [3–10], especially in
patients with persistent hypercortisolism (3.7–4.2) com-
pared to those in remission (1.8–3.17). SMR is higher in
CD patients compared to those undergoing TSS for non-
functioning pituitary macroadenomas (NFPA) (2.39 vs.
1.24) [6].
Cardiovascular and cerebrovascular events are the
most common cause of death in CD [6, 9]. In one
study, CD patients died of cardiovascular disease
(n = 4), cerebrovascular disease (n = 1), malignancy
(n = 1), and infectious diseases (n = 1). The average
age at death (62.4 years) was significantly lower than
that seen in the general Dutch population [6]. Thus,
normalization of cortisol levels improves but does
not normalize mortality compared to the general
population.
Comorbidities in CD (Table 1)
Cardiovascular disease
Prolonged exposure to hypercortisolemia is associated with
multiple cardiovascular risk factors that strongly impact
morbidity and mortality. These risk factors include visceral
adiposity, systemic arterial hypertension, impaired glucose
tolerance, dyslipidemia and hypercoagulability [1].
Cardiovascular risk is increased in CD patients even
5 years after remission [11, 12]. Compared with controls,
CD patients had significantly higher waist-to-hip ratio, di-
astolic blood pressure (BP), oral glucose tolerance test
(OGTT)—stimulated glucose and insulin levels, total/HDL
cholesterol ratio and fibrinogen levels. These patients had
increased atherosclerotic carotid artery changes, with higher
intima-media thickness and lower distensibility coefficient
on ultrasound imaging. Atherosclerotic plaques were found
in 26.7 % of CD patients and\4 % of controls [11].
Table 1 Summary of comorbidities and their prevalence in active Cushing’s disease
Comorbidities Prevalence References
Cardiovascular/metabolic
Obesity 32–41 % [13–16]
Impaired glucose tolerance 21–64 % [3, 7, 11, 15,
16]
Diabetes mellitus 20–47 % [3, 7, 11, 15,
16]
Hypertension 55-85 % [11, 15–18]
Dyslipidemia 38-71 % [11, 16]
Hypercoagulopathy—hemostatic abnormalities 54 % [22–25]
Hypercoagulopathy—venous thromboembolism Incidence: 2.5–14.6/1000 persons/
year
[25, 27]
Atherosclerotic changes 27–31 % [11, 12, 15]
Cardiac structural and functional alterations 23–62 % [19–21]
Bone
Osteoporosis 38–50 % [5, 34–36]
Fractures (vertebral and rib fractures) 15–50 % [5, 34–36]
Kidney
Nephrolithiasis 50 % [41]
Psychiatric dysfunction
Overall psychopathology 67 % [42, 45]
Major depression 55–80 % [43, 44]
Mood lability, irritability, anxiety, mania, psychosis, maladaptive personality [42–46]
Cognitive impairment [47–53]
Deficits in memory, verbal learning, spatial information, language and executive
functioning
[52]
Subjective loss of brain volume 86 % [50]
Hippocampal atrophy 27 % [47]
White matter integrity changes [53]
Poor health-related quality of life (HRQoL) [54–58]
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Both children and adults in biochemical remission have
abnormally high total body fat and visceral to subcutaneous
fat ratios after a follow-up of 3–11 years [13, 14]. The adult
patients also have increased inflammatory markers and
decreased adiponectin levels [14]. This persistence of cen-
tral adiposity and an unfavorable adipokine profile may link
metabolic alterations and cardiovascular morbidity in CD.
Hypertension occurs in 55–85 % of CD patients [11, 15,
16], but resolves after remission in only 44–75 % [14, 16,
17]. Persistent hypertension despite remission may be re-
lated to microvessel remodeling and/or presence of un-
derlying essential hypertension. Older age, longer duration
of exposure to hypercortisolemia and a longer duration of
untreated hypertension are associated with persistently
elevated BP after biochemical cure [16–18]. This underlies
the importance of early control of hypertension even while
establishing the diagnosis of CD.
Cardiac structural and functional alterations, including
left ventricular hypertrophy, concentric remodeling, and
reduced mid-wall systolic performance with diastolic dys-
function, occurs in active CD [19–21]. They are more
severe in hypertensive patients, suggesting an interaction
between the deleterious effects of hypertension and cortisol
excess per se [19]. With remission of hypercortisolemia,
cardiac alterations significantly improve [19, 21] but may
not normalize [19].
Patients with CD have an increased predisposition to
thromboembolic events, especially in the perioperative pe-
riod, likely related to a procoagulative phenotype due to
cortisol excess [22–24]. In one systematic review, the inci-
dence of venous thromboembolism (VTE) in CS was
2.5–3.1 per 1000 persons/year [25] compared to 1.0–2.0 per
1000 persons/year in the general population [26]. In a mul-
ticenter retrospective cohort study of 473 CS patients (360
CD), the incidence of VTE before treatment of hypercorti-
solemia was 14.6 per 1000 persons/year [27]. Additionally,
the incidence of postoperative VTE was significantly greater
compared to patients who underwent TSS for NFPAs (3.4
vs. 0 %) with the highest risk being in the first 2 months after
surgery [27]. However, biochemical remission of hyper-
cortisolemia with medical therapy (80 days) did not nor-
malize hemostatic and fibrinolytic parameters [23]. At
present, the duration and severity of risk for VTE following
remission of hypercortisolism remain uncertain. There are
no clear guidelines on the dose and duration of thrombo-
prophylaxis either before or after surgery. Future long-term
studies are needed to evaluate these issues.
Insulin resistance, impaired glucose tolerance
and diabetes mellitus
Insulin resistance is a well-known complication of CD.
Glucocorticoid excess induces the expression of several
key gluconeogenesis enzymes resulting in increased glu-
cose production. It also impairs insulin sensitivity via direct
interference with the insulin receptor signaling pathway as
well as indirectly, through the stimulation of lipolysis and
proteolysis [28]. The prevalence of overt diabetes mellitus
is 20–47 % and that of impaired glucose tolerance is
21–64 % in CD [1, 11, 15, 16]. This may be an underes-
timation as not all patients undergo an OGTT, which is
needed to diagnose impaired glucose tolerance when the
fasting glucose is normal. The homeostatic model assess-
ment (HOMA) shows decreased insulin sensitivity index
(ISI) and increased insulin resistance in CD. Normal
weight, overweight and obese patients have similar values,
suggesting that these alterations result from hypercorti-
solemia and not obesity [14, 16]. Age, genetic predisposi-
tion and lifestyle also contribute significantly to the
development of glucose intolerance in CD [29].
Dyslipidemia
Lipid abnormalities (increased total and LDL cholesterol,
triglycerides and total/HDL cholesterol ratio) occur in
38–71 % of CD patients [11, 16]. The multifactorial
pathogenic mechanisms include direct and indirect actions
of cortisol on lipolysis, free fatty acid production and
turnover, very-low density lipoprotein synthesis and fatty
accumulation in the liver. Insulin resistance, growth hor-
mone deficiency and hypogonadism are also contributing
factors [30]. Given the increased cardiovascular morbidity
and mortality in CD, aggressive treatment of dyslipidemia
is recommended [31]. Surgical remission is often associ-
ated with normalization of lipid abnormalities.
Management of dyslipidemia can be challenging in pa-
tients on medical therapy. Mitotane significantly increases
cholesterol levels [32]. Drug interactions are common with
ketoconazole, a potent inhibitor of cytochrome P450 3A4
(CYP3A4). Concomitant use of ketoconazole and certain
statins (e.g. simvastatin and atorvastatin) that undergo
metabolism via CYP3A4 can lead to significantly higher
plasma levels of the statin, thus increasing the risk of
complications and side-effects. In this setting, preference
should be given to agents that are not metabolized by the
CYP3A4 pathway (e.g. pravastatin) with close monitoring
of liver function tests [31, 33].
Osteoporosis, fractures and nephrolithiasis
The prevalence of fractures and osteoporosis as assessed by
dual energy X-ray absorptiometry (DXA) has been re-
ported to be 15–50 and 38–50 % respectively [5, 34–36],
and may be a presenting feature of CD. These rates are
likely an underestimation as not all CD patients undergo
DXA scans, and asymptomatic vertebral and rib fractures
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can remain undiagnosed. The prevalence of vertebral and
rib fractures is significantly higher in men compared to
women [5]. This results from direct and indirect effects of
glucocorticoids on bone, including decreased osteoblastic
and increased osteoclastic activity, hypogonadism, growth
hormone deficiency, reduced intestinal calcium absorption
and increased urinary calcium excretion [37].
Normalization of cortisol levels has been associated
with reversal of glucocorticoid-induced osteoporosis after
6–9 years [38, 39]. However, other shorter studies with
2–3 years follow-up show incomplete recovery of bone
mineral density and quality of bone after remission [36, 40].
Nephrolithiasis is reported in 50 % of active CD patients
compared to 6.5 % in age- and gender-matched controls.
This is accompanied by hypercalciuria, hypocitraturia,
hyperuricosuria and hyperoxalaturia [41], with ameliora-
tion of this lithogenic excretion pattern after remission.
During remission, the prevalence of nephrolithiasis de-
creases (27.3 %) but remains higher compared to controls
[41].
Psychiatric dysfunction
Most (54–85 %) patients with CD have some psychiatric
disturbance. Depression and irritability are most common
emotional lability, mania, paranoia, acute psychosis,
anxiety and panic attacks also occur [42, 43]. Many of
these symptoms persist in the first few years after suc-
cessful surgery [44–46]. However, overall psy-
chopathology decreased significantly from 66.7 % during
active CD to 53.6 % at 3 months, 36 % at 6 months and
24.1 % at 12 months after remission [44]. In another study,
CD patients achieving long-term (mean 11 years) remis-
sion showed an increased prevalence of psychopathology
and maladaptive personality traits compared to those with
NFPAs and matched controls. These observations suggest
irreversible effects of cortisol excess on the central nervous
system rather than an effect of pituitary tumors or their
treatment [46].
Cognitive impairment
Chronic hypercortisolism is associated with cognitive dys-
function including impairment of memory, visual and spa-
tial information, reasoning, verbal learning and language
performance [47–53]. The hippocampus, amygdala and the
cerebral cortex, structures important for cognitive and
emotional functioning, are rich in glucocorticoid receptors
and presumably particularly vulnerable to hypercorti-
solemia. Hippocampal atrophy was seen in 27 % of 12
active CS patients and correlated with performance on
cognitive tests [47]. Hippocampal formation volume in-
creased by up to 10 % in 22 CD patients *16 months after
surgical remission of hypercortisolemia [51]. In a case
control study, apparent loss of brain volume was noted in
86 % of CD patients (14 % mild, 43 % moderate, 29 %
severe), 100 % of adrenal CS patients and 10 % of controls.
Normalization of cortisol levels was associated with partial
reversal of cerebral atrophy [50]. van der Werff et al. re-
ported widespread reductions in fractional anisotropy
(marker of tissue microstructural organization) and changes
of white matter integrity in 22 CD patients in long-term
remission (mean 11.9 years) compared with matched con-
trols, with changes in the uncinate fasciculus being related
to the severity of depressive symptoms [53]. Recently
Tiemensma et al. [52] reported significantly lower scores on
cognitive assessment tests reflecting impaired memory and
executive functioning, in 74 CD patients despite long-term
remission (mean 13 years) compared with age-, gender- and
education-matched controls. These data suggest that the
structural changes in the brain induced by hypercorti-
solemia are at least partially reversible with normalization
of cortisol levels. However, there may be a delay of several
years from eucortisolemia to the resolution of cognitive
deficits, and occasionally these may be irreversible.
Health related quality of life (HRQoL)
HRQoL is significantly impaired in patients with CD [54–
57]. In one study, the issues most often reported by CS
patients with regards to the impact of the disease on their
everyday life were fatigue and weakness (85 %), interfer-
ence with family life and relationship with their partners
(80 %), changes in physical appearance (63 %), emotional
instability (61 %), impaired school/work performance
(56 %), cognitive problems (49 %), depression (32 %) and
sleeping difficulties (12 %) [51]. A prospective study of
HRQol using the short-form 36 (SF-36) survey in 23 CD
patients before and after TSS demonstrated that active CD
was associated with low physical and mental summary
scores with partial resolution after surgical remission of
hypercortisolemia [55]. In a recent cross-sectional study of
102 patients with surgically treated CD (mean time since
surgery 7.4 years), 92 % met the criteria for biochemical
remission but only 80 % felt that they had been cured.
These findings reflect the discordance between biochemical
and self-assessed disease status and its impact on HRQoL
in CD patients [57]. In a recent systematic review of
quality of life impairments in patients with pituitary ade-
nomas, biochemical remission of CD was associated with
the smallest improvement in QoL measurements compared
to those with other pituitary adenomas. Somatic factors
(including hypopituitarism), psychological factors (illness
perceptions), and health care environment (rural vs. urban)
were identified as influencing factors [58].
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Economic burden of CD
Swearingen et al. analyzed data from a US administrative
claims database for the period 2004–2008 with data on
hospital admissions, physician visits, emergency room
visits and medication use. The total health care costs for
CD patients were fourfold greater than age- and gender-
matched population controls and twofold higher than age-
and gender-matched patients with NFPAs. Annual outpa-
tient costs decreased significantly after surgical remission.
In contrast, there was a significant increase in postoperative
health care costs in those patients not in remission [59]. A
more recent analysis of health care costs in CD based on
2010 US claims data estimated the total cost of care at
$35,000/year [60]. These data along with the decreased
working ability of CD patients and increase in sick leave
highlight the significant economic burden placed on the
patients as well as on the health care resources in CD.
Conclusion
Although rare, CD is associated with a significant clinical,
social, economic and quality of life burden. Uncontrolled
hypercortisolemia is associated with metabolic, cardio-
vascular, cognitive and psychological alterations leading to
increased mortality. Normalization of cortisol levels leads
to significant improvement in these parameters and de-
creased mortality. However a growing body of evidence
indicates that many risks and morbidities, in particular
cardiovascular risk, persist for several years after remis-
sion. Larger studies with long-term follow-up are needed to
elucidate this further. Early diagnosis and control of hy-
percortisolemia, aggressive management of comorbidities
in a multidisciplinary setting and long-term follow-up are
essential for optimal recovery in CD.
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